Aradigm
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aradigm - overview
Established
2024
Location
New York, NY, US
Primary Industry
Pharmaceuticals
About
Aradigm is a specialized biotechnology firm focused on developing innovative drug delivery systems that enhance therapeutic efficacy for chronic respiratory diseases. Their unique formulations aim to improve treatment outcomes for patients. Founded in Hayward, US, Aradigm is dedicated to advancing drug delivery technologies. In December 2025, Aradigm raised USD 20 million in series A funding led by new investor Frist Cressey Ventures, with participation from other new investors Andreessen Horowitz and Morgan Health.
Aradigm specializes in advanced drug delivery systems designed for chronic respiratory conditions. Their core offerings focus on innovative formulations that improve therapeutic efficacy, catering to the healthcare sector. The products are distributed across North America, Europe, and select Asian markets, serving a diverse clientele ranging from healthcare providers to pharmaceutical companies. Aradigm's revenue model primarily relies on the commercialization of its drug delivery technologies, with clients typically engaging in long-term contracts for product supply.
The company plans to utilize the December 2025 funding to speed up the development of its platform and increase collaborations with health systems and insurance providers.
Current Investors
First Eagle Investment Management, Novo Nordisk A/S, Tavistock Group
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.aradigm.com
Verticals
Artificial Intelligence, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.